# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company commi...
2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High...
Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congres...
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.17) b...
Goldman Sachs analyst Paul Choi maintains Amarin Corp (NASDAQ:AMRN) with a Sell and raises the price target from $7 to $12.